Mesothelioma is a rare and fast acting tumor where no helpful therapy has been discovered even with the finding of quite a few probable genetic targets. The late stage of Malignant pleural mesothelioma diagnosis and the period of time that exists connects contacts and diagnosis have made it hard to fully study what risk factors do and the insuing molecular effects.

Many health centres are witnessing increasing numbers of patients that are suffering from mesothelioma cancer. Because of this, pathologists studying the case are given a number of problems, that are divided into those discovered in making the distinction between cancer of the mesothelium and benign changes and those discovered in differentiating malignant mesotheliomas from different forms of e-cadherin and tissue tumors that connect. IHC plays a major role in diagnosing, but it should be interpreted in regards to the experimental setting and radiological characteristics, and with a knowledge of the broad morphological variations existing in mesothelioma.

Malignant mesothelioma is a cancer directly affecting the serosal cavities, an anatomic location that is often affected by mets, mostly from primary carcinomas of the lung, breast, and ovary. Progression in IHC have lead to improved diagnostic sensitivity and between metastatic adenocarcinoma and {malignant mesothelioma in regards to histological and cytological material. Lately, the researchers applied a high level of throughput technology to the recognition of new flags that could help in being able to tell the difference between mesothelioma from ovarian and peritoneal serous carcinoma, tumors with closely related histogenesis and antigenic profile. In addition to the better tools available for serosal carcinoma diagnosis, realizing the biology of mesothelioma has been accumulating in recent years.